Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
194 hedge funds and large institutions have $1.25B invested in Acorda Therapeutics in 2016 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 81 increasing their positions, 56 reducing their positions, and 28 closing their positions.
45% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 56
32% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 28
4% more funds holding
Funds holding: 186 → 194 (+8)
39% less capital invested
Capital invested by funds: $2.05B → $1.25B (-$809M)
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
86% less call options, than puts
Call options by funds: $1.28M | Put options by funds: $9.34M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$35.6M |
| 2 |
SCM
Scopia Capital Management
New York
|
+$24.3M |
| 3 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$21.9M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$17.2M |
| 5 |
Morgan Stanley
New York
|
+$13.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$50.5M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$49M |
| 3 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$34.9M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$28M |
| 5 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$20.2M |
ACOR Hedge Fund Activity: Q1 2016 in Review
194 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q1 2016, worth a combined $1.25B — down 39% from $2.05B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new ACOR positions and 28 closed out — a net gain of 9 holders — while 81 added to existing stakes and 56 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $35.6M. The largest seller was Thrivent Financial for Lutherans, cutting an estimated $50.5M.
- 194 institutional investors held Acorda Therapeutics (ACOR) as of Q1 2016, up from 186 in Q4 2015.
- Funds reported $1.25B of Acorda Therapeutics stock for Q1 2016, down 39% quarter-over-quarter.
- 37 funds opened new Acorda Therapeutics positions in Q1 2016 and 28 closed out, a net change of +9 holders.
- The largest Acorda Therapeutics buyer in Q1 2016 was Deerfield Management, an estimated $35.6M added.
- The largest Acorda Therapeutics seller in Q1 2016 was Thrivent Financial for Lutherans, an estimated $50.5M sold.
Based on aggregated 13F filings for Q1 2016.